Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone-sensitive Metastatic Breast Cancer”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Not applicableStudy completedNCT06307457
What this trial is testing

HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Who this might be right for
Breast Cancer
Pfizer 604
Testing effectiveness (Phase 2)Study completedNCT00454805
What this trial is testing

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

Who this might be right for
Advanced Breast Cancer
AstraZeneca 75
Testing effectiveness (Phase 2)Ended earlyNCT01627067
What this trial is testing

Exemestane-RAD001-Metformin

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 23
Testing effectiveness (Phase 2)WithdrawnNCT00057993
What this trial is testing

Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
Northwestern University
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Testing effectiveness (Phase 2)WithdrawnNCT01005641
What this trial is testing

ELBA: Exemestane and Lapatinib in Advanced Breast Cancer

Who this might be right for
Breast Cancer
National Cancer Institute, Naples
Not applicableStudy completedNCT01720602
What this trial is testing

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

Who this might be right for
Male Breast CancerRecurrent Breast CancerStage IV Breast Cancer
University of Washington 15
Early research (Phase 1)Study completedNCT00933309
What this trial is testing

The Impact of Obesity and Obesity Treatments on Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 25
Testing effectiveness (Phase 2)Ended earlyNCT01205685
What this trial is testing

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Who this might be right for
Hormone-sensitive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center 11
Early research (Phase 1)Study completedNCT04712396
What this trial is testing

Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Who this might be right for
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
AstraZeneca 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT06590857
What this trial is testing

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Who this might be right for
Metastatic Breast CancerHER2-negative Breast CancerER+ Breast Cancer+7 more
RayzeBio, Inc. 16
Testing effectiveness (Phase 2)WithdrawnNCT01013506
What this trial is testing

Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center
Testing effectiveness (Phase 2)UnknownNCT00927511
What this trial is testing

A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)

Who this might be right for
Breast Cancer
Regina Elena Cancer Institute 104
Testing effectiveness (Phase 2)Study completedNCT00871858
What this trial is testing

Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer

Who this might be right for
Breast Cancer
Institut Bergonié 120
Testing effectiveness (Phase 2)Study completedNCT01446159
What this trial is testing

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Who this might be right for
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
MedImmune LLC 188
Testing effectiveness (Phase 2)Study completedNCT00240071
What this trial is testing

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

Who this might be right for
Metastatic Breast Cancer
University of Alabama at Birmingham 30
Testing effectiveness (Phase 2)Study completedNCT00602043
What this trial is testing

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerProgesterone Receptor-negative Breast CancerProgesterone Receptor-positive Breast Cancer+2 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)UnknownNCT02690480
What this trial is testing

Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Spanish Breast Cancer Research Group 189